AI-assisted, human-published
05/07/2025 /Funding Events
PAQ Therapeutics Secures $39M Series B Funding for Clinical Development of PT0253
PAQ Therapeutics secures $39 million in Series B funding to advance the clinical development of PT0253, a potent and selective KRAS G12D degrader, and doses its first patient in a Phase 1 study.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com